Lineage Cell Therapeutics launches preclinical COR1 program for corneal endothelial disease

Lineage Cell Therapeutics has initiated a preclinical program evaluating an allogeneic corneal endothelial cell (CEnC) therapy, COR1, for the treatment of corneal endothelial disease, including Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy. The announcement reflects continued industry interest in cell-based approaches aimed at addressing the global shortage of donor corneal tissue and the limitations of current surgical management.

Corneal endothelial dysfunction remains a leading indication for keratoplasty worldwide, with FECD accounting for a substantial proportion of cases.¹ The introduction of an “off-the-shelf” cell therapy approach, if successful, could offer a less invasive alternative to transplantation and potentially expand access to treatment, particularly in regions with limited donor supply.

Program overview and preclinical development

According to the company, COR1 is being developed using a proprietary pluripotent stem cell–derived platform designed to generate scalable, allogeneic corneal endothelial cells. These cells are intended for intracameral injection, with subsequent adherence to the posterior corneal surface (Descemet membrane) to restore endothelial pump function.

The program is currently in preclinical development, and no in vivo efficacy or safety data have been publicly disclosed. Lineage reported that its manufactured cells demonstrate morphology and functional characteristics consistent with corneal endothelial identity based on internal criteria, though these findings have not yet been validated in peer-reviewed studies.

The company’s manufacturing approach relies on a two-tiered cell banking system derived from a single pluripotent cell line, aiming to enable large-scale production and consistency across batches. While this strategy aligns with broader trends in regenerative medicine, clinical translation will depend on demonstrating durability, safety, and reproducibility in human studies.

Clinical context and unmet need

FECD is a progressive degenerative disorder characterized by endothelial cell loss and the development of guttae, leading to corneal edema and vision impairment.² The condition disproportionately affects older adults and is a major driver of endothelial keratoplasty procedures such as Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping automated endothelial keratoplasty (DSAEK).³

Despite advances in surgical techniques, access to donor corneas remains a critical constraint. A widely cited global analysis estimated that only 1 cornea is available for every 70 patients requiring transplantation.⁴ This disparity has prompted interest in alternative strategies, including tissue engineering, cell injection therapies, and pharmacologic approaches such as Rho kinase (ROCK) inhibitors.

Early clinical work in Japan has demonstrated the feasibility of corneal endothelial cell injection therapy using cultured human cells in combination with ROCK inhibition, with reported improvements in corneal clarity and visual acuity in patients with bullous keratopathy.⁵ These findings provide proof-of-concept for the therapeutic approach underlying programs such as COR1, although differences in manufacturing, cell source, and regulatory standards may affect generalizability.

Mechanism and therapeutic rationale

Corneal endothelial cells play a critical role in maintaining stromal deturgescence through active ion transport. Loss of these cells leads to fluid accumulation and loss of corneal transparency. Unlike other corneal layers, endothelial cells have limited proliferative capacity in vivo, making cell replacement an attractive therapeutic strategy.

Allogeneic cell therapy aims to bypass the need for donor tissue by providing a standardized, scalable source of functional endothelial cells. However, key challenges include ensuring cell survival, integration, immune tolerance, and long-term function following injection.

Interpretation and limitations

The COR1 program remains at an early stage, and its clinical potential is uncertain. No animal or human data have been released, limiting the ability to assess efficacy, dosing, or safety risks such as immunogenicity or ectopic cell growth. Additionally, manufacturing claims have not been independently verified in published literature.

The broader field of corneal endothelial cell therapy is evolving, with ongoing efforts to refine delivery techniques, optimize adjunctive therapies (eg, ROCK inhibitors), and establish regulatory pathways. Whether a fully allogeneic, off-the-shelf product can achieve outcomes comparable to established surgical approaches remains to be determined.

Next steps

Advancement into formal preclinical studies, including in vivo models, will be necessary to support investigational new drug (IND) applications and eventual clinical trials. Key endpoints will likely include corneal thickness, endothelial cell density, visual acuity, and safety outcomes.

If successful, COR1 could contribute to a growing pipeline of regenerative therapies aimed at reducing reliance on donor tissue. However, clinical validation and long-term follow-up data will be essential before its role in practice can be defined.

References:

1. Eye Bank Association of America. 2022 Eye Banking Statistical Report. Accessed March 24, 2026. https://restoresight.org/statistical-report/

2. Ong Tone S, Kocaba V, Böhm M, Wylegala A, White TL, Jurkunas UV. Fuchs endothelial corneal dystrophy: the vicious cycle of Fuchs pathogenesis. Prog Retin Eye Res. 2021;80:100863. https://doi.org/10.1016/j.preteyeres.2020.100863

3. Price MO, Price FW Jr. Endothelial keratoplasty—a review. Clin Exp Ophthalmol. 2010;38(2):128-140. https://doi.org/10.1111/j.1442-9071.2010.02254.x

4. Gain P, Jullienne R, He Z, et al. Global survey of corneal transplantation and eye banking. JAMA Ophthalmol. 2016;134(2):167-173. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2471498

5. Kinoshita S, Koizumi N, Ueno M, et al. Injection of cultured corneal endothelial cells in patients with bullous keratopathy. N Engl J Med. 2018;378(11):995-1003. https://www.nejm.org/doi/full/10.1056/NEJMoa1712770